ICD-10-CM Billable Code

P78.84

Gestational alloimmune liver disease

Clinical Classification Guidelines

Inclusion Terms

  • GALD
  • Neonatal hemochromatosis

Excludes Type 1

  • hemochromatosis (E83.11-)

Medical Intelligence & Overview

Gestational alloimmune liver disease (GALD), also known as neonatal hemochromatosis, is a rare but serious condition that affects newborns. It occurs when a mother's immune system mistakenly targets her baby's liver, leading to significant liver damage. Recognized under the ICD-10 code P78.84, GALD is an important diagnosis to understand as it can impact a child's health dramatically if not identified and managed promptly. This disease is characterized by liver failure due to immune-mediated injury and is often associated with abnormal iron deposits in the liver and other organs.

Causes & Symptoms

Clinical Causes: Maternal immune system producing antibodies that attack fetal liver tissues Presence of maternal alloimmune antibodies crossing the placenta and targeting fetal liver cells Genetic predispositions that may enhance susceptibility to immune-mediated damage Absence of other underlying metabolic or infectious causes of liver disease

Key Symptoms: Signs of jaundice in the newborn, including yellowing of the skin and eyes Poor feeding and irritability Failure to thrive or weight loss Liver enlargement or tenderness Ecchymosis or bleeding tendencies due to impaired clotting function Signs of liver failure such as edema, ascites, or bleeding in severe cases In some cases, manifestations of other organ involvement due to iron overload

Diagnostic & Treatment

Diagnosis Path: Diagnosing GALD involves a combination of clinical evaluation, laboratory tests, and imaging studies. Key steps include: - Blood tests revealing elevated liver enzymes, bilirubin, and abnormal coagulation profiles - Magnetic resonance imaging (MRI) to assess liver structure and iron overload - Liver biopsy, which may show characteristic iron deposits and liver tissue damage - Detection of maternal alloimmune antibodies that target fetal liver cells - Exclusion of other causes of neonatal liver disease Early recognition and diagnosis are vital for initiating appropriate treatment strategies and improving outcomes.

Treatment Protocols: Management of GALD focuses on controlling liver damage, reducing immune-mediated injury, and supporting liver function. Treatment options include: - Intravenous immunoglobulin (IVIG) therapy to diminish maternal antibody effects - Exchange transfusions to remove pathogenic antibodies - Supportive care such as nutritional support, transfusions for anemia, and management of bleeding or clotting issues - Liver transplantation in advanced cases of liver failure - Close monitoring for iron overload and organ function A multidisciplinary approach involving neonatologists, hepatologists, and immunologists is crucial for optimal care. Early intervention can significantly improve prognosis and reduce the risk of long-term complications.

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.

Clinical Advice & FAQs

Billing Guidance

Is P78.84 a billable ICD-10 code?
Yes, P78.84 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.

Documentation

How do I report P78.84?
Clinical documentation must specify the nature of Gestational alloimmune liver disease and any associated comorbidities for accurate reporting.

Cite this Clinical Reference

Clinical Meta Tags

gestational alloimmune liver disease